Acasă › Mielom multiplu › Missouri › St. Louis
Studii clinice pentru Mielom multiplu în St. Louis, MO
24 studii pentru Mielom multiplu caută participanți în și în jurul orașului St. Louis (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
În curs de recrutareFaza 2
- Washington University School Of Medicine, St Louis
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
În curs de recrutareFaza 1/2
- Washington University School of Medicine, St Louis
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
În curs de recrutareFaza 1
- Research Site, St Louis
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 2
- Washington University School Of Medicine, St Louis
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
În curs de recrutareFaza 4
- Washington University School Of Medicine, St Louis
Collection of Tissue Samples for Cancer Research
În curs de recrutareStudiu observațional
- Washington University - St. Louis, St Louis
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 2
- Washington University School of Medicine, St Louis
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
În curs de recrutareFaza 3
- Washington University School of Medicine, St Louis
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 1/2
- Research Site, St Louis
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
În curs de recrutareFaza 2
- GSK Investigational Site, Bridgeton · La 15 mi distanță
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
În curs de recrutareFaza 3
- Mercy Infusion Center - Chippewa, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- și încă 4
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
În curs de recrutareFaza 3
- Research Site, St Louis
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
În curs de recrutareFaza 2
- Washington University School of Medicine, St Louis
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
În curs de recrutareFaza 2
- Washington University/Siteman Cancer Center, St Louis
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
În curs de recrutareFaza 1
- Washington University School of Medicine, St Louis
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
În curs de recrutare
- Washington University School of Medicine, St Louis
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
În curs de recrutareFaza 1
- Washington University School of Medicine, St Louis
64Cu-LLP2A for Imaging Hematologic Malignancies
În curs de recrutareFaza 1 timpurieVoluntari sănătoși bineveniți
- Washington University School of Medicine, St Louis
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
În curs de recrutareFaza 3
- Saint Louis Cancer and Breast Institute-South City, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- și încă 5
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
În curs de recrutareFaza 1
- Washington University School of Medicine, St Louis
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
În curs de recrutare
- Washington University School of Medicine, St Louis
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 1
- Washington University /ID# 266972, St Louis
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
În curs de recrutareFaza 3
- Saint Louis University, St Louis
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
În curs de recrutareFaza 1
- Washington University School of Medicine, St Louis
Studii pentru Mielom multiplu în alte orașe
- New York City, NY60 studii
- Boston, MA42 studii
- Atlanta, GA41 studii
- Houston, TX38 studii
- Durham, NC37 studii
- Nashville, TN32 studii
- Denver, CO27 studii
- Rochester, MN24 studii
- Columbus, OH24 studii
- Baldwin Park, CA23 studii
- Chicago, IL22 studii
- Seattle, WA22 studii
Alte studii în St. Louis
- Cancer pulmonar cu celule non-pătrate73 studii
- Cancer de sân64 studii
- Cancer metastatic54 studii
- Cancer colorectal50 studii
- Cancer de prostată46 studii
- Cancer (toate tipurile)46 studii
- Cancer pulmonar39 studii
- Cancer ovarian38 studii
- Cancer pancreatic33 studii
- Cancer endometrial29 studii
- Carcinom cu celule scuamoase de cap și gât28 studii
- Insuficiență cardiacă26 studii
Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.